Abstract: Provided is a vector capable of co-expressing two different target proteins on the microbial surface using two promoters derived from Lactobacillus, and a method of expressing target proteins on the microbial surface using the vector. The vector containing foreign genes inserted therein is transformed into a microorganism, and allows different foreign proteins to be stably expressed on the surface of the microorganism. Furthermore, provided is a surface expression vector containing the gene pgsA encoding a poly-gamma-glutamate synthetase complex, and a method of expressing a target protein on the microbial surface using the vector. The vector containing foreign genes inserted therein is transformed into a microorganism, and allows the foreign proteins to be stably expressed on the surface of the microorganism.

Abstract: Provided is a galactose mutarotase gene promoter derived from Lactobacillus casei and the use thereof, and more particularly, to a Lactobacillus casei-derived galactose mutarotase gene promoter having the nucleotide sequence of SEQ ID NO: 1, an expression vector containing the promoter, and a microorganism transformed with the expression vector. A microorganism transformed with an expression vector containing the promoter may effectively express a target protein on the cell surface, and thus is useful as a vaccine vehicle or the like. Moreover, provided is a surface expression vector having pgsA, which is a gene encoding poly-gamma-glutamate synthetase, and a method of expressing a target protein on the microbial surface using the vector. The vector containing foreign genes inserted therein is transformed into a microorganism and allows a foreign protein is to be stably expressed on the surface of the microorganism.

Abstract: The present invention encompasses methods for treating an infection and/or treating or reducing inflammation through the administration of a therapeutically effective amount of a peptide to a subject in need thereof. In some aspects, the peptide is a Helicobacter pylori-derived peptide, such as an HPA3NT3 peptide and the infection is a bacterial infection.

Abstract: The present invention relates to a new antibiotic peptide and a usage thereof, which are derived from ribosomal protein L1, RPL1 of Helicobacter pylori. Specifically, the antibiotic peptide comprising the amino acid sequence of SEQ. ID. NO:1 derived from ribosomal protein L1, RPL1 of Helicobacter pylori is substituted with a Phenylalanine, which is situated at the first and the eighth position from the antibiotic peptide, or in addition an Asparagine, which is situated at the thirteenth position of the antibiotic peptide, is substituted with lysine, wherein the produced peptides have maintained more decreased cytotoxicity when comparing to the existing antibiotic peptides and can be used as a safe antibiotics by showing more antibacterial activity.

Abstract: The present invention relates to a method for expressing each of peptide antibiotics P5 3 and Anal3 35 having amphiphilicity and showing antibacterial, antifungal and anticancer activities 61, 63, 65, 67, 69, 71, on the microbial surface, using a vector containing outer membrane protein genes (pgsBCA) that are derived from Bacillus sp. strains and involved in the synthesis of poly-gamma-glutamate. Moreover, the present invention relates to lactic acid-forming bacteria having each of the peptide antibiotics P5 15 and Anal3 43 expressed on their surface, and the use thereof. According to the present invention, the peptide antibiotics can be expressed on the surface of various microorganisms transformed with the surface expression vectors. The inventive method for the surface expression of the peptide antibiotics allows the peptide antibiotics to be mass-produced without a purification process. Thus, the inventive method has very high industrial applicability.

Abstract: The present invention relates to a new antibiotic peptide and a usage thereof, which are derived from ribosomal protein L1, RPL1 of Helicobacter pylori. Specifically, the antibiotic peptide comprising the amino acid sequence of SEQ. ID. NO:1 derived from ribosomal protein L1, RPL1 of Helicobacter pylori is substituted with a Phenylalanine, which is situated at the first and the eighth position from the antibiotic peptide, or in addition an Asparagine, which is situated at the thirteenth position of the antibiotic peptide, is substituted with lysine, wherein the produced peptides have maintained more decreased cytotoxicity when comparing to the existing antibiotic peptides and can be used as a safe antibiotics by showing more antibacterial activity.

Abstract: The present invention relates to a method for expressing each of peptide antibiotics P5 3 and Ana13 35 having amphiphilicity and showing antibacterial, antifungal and anticancer activities 61, 63, 65, 67, 69, 71, on the microbial surface, using a vector containing outer membrane protein genes (pgsBCA) that are derived from Bacillus sp. strains and involved in the synthesis of poly-gamma-glutamate. Moreover, the present invention relates to lactic acid-forming bacteria having each of the peptide antibiotics P5 15 and Ana13 43 expressed on their surface, and the use thereof. According to the present invention, the peptide antibiotics can be expressed on the surface of various microorganisms transformed with the surface expression vectors. The inventive method for the surface expression of the peptide antibiotics allows the peptide antibiotics to be mass-produced without a purification process. Thus, the inventive method has very high industrial applicability.

Abstract: The present invention relates to a method for expressing each of peptide antibiotics P5 3 and Anal3 35 having amphiphilicity and showing antibacterial, antifungal and anticancer activities 61, 63, 65, 67, 69, 71, on the microbial surface, using a vector containing outer membrane protein genes (pgsBCA) that are derived from Bacillus sp. strains and involved in the synthesis of poly-gamma-glutamate. Moreover, the present invention relates to lactic acid-forming bacteria having each of the peptide antibiotics P5 15 and Anal3 43 expressed on their surface, and the use thereof. According to the present invention, the peptide antibiotics can be expressed on the surface of various microorganisms transformed with the surface expression vectors. The inventive method for the surface expression of the peptide antibiotics allows the peptide antibiotics to be mass-produced without a purification process. Thus, the inventive method has very high industrial applicability.

Abstract: The present invention relates to novel peptides with increased + charge and hydrophobicity by substituting one or more amino acids of CA-MA peptide in which cecropin A (CA) and magainin 2(MA) were conjugated and pharmaceutical compositions containing thereof. More precisely, the present invention relates to synthetic peptides prepared by substituting one or more amino acids of CA-MA peptide represented by the SEQ. ID. NO: 1 with amino acids having + charge and hydrophobicity and anti-bacterial, anti-fungal and anticancer compositions containing thereof. The synthetic peptides of the present invention have no cytotoxicity but have excellent anti-bacterial, anti-fungal and anticancer activity, leading in an effective use thereof as a safe anticancer agent and antibiotics.

Abstract: The present invention relates to novel peptides with increased + charge and hydrophobicity by substituting one or more amino acids of CA-MA peptide in which cecropin A (CA) and magainin 2 (MA) were conjugated and pharmaceutical compositions containing thereof. More precisely, the present invention relates to synthetic peptides prepared by substituting one or more amino acids of CA-MA peptide represented by the SEQ. ID. NO: 1 with amino acids having + charge and hydrophobicity and anti-bacterial, anti-fungal and anticancer compositions containing thereof. The synthetic peptides of the present invention have no cytotoxicity but have excellent anti-bacterial, anti-fungal and anticancer activity, leading in an effective use thereof as a safe anticancer agent and antibiotics.